1146412-06-7

Basic information

• Product Name: methyl N-{2-[(2-cyano-4-fluorophenyl)amino]ethyl}-N-{[(1,1-dimethylethyl)oxy]carbonyl}glycinate
• Synonyms: methyl N-{2-[(2-cyano-4-fluorophenyl)amino]ethyl}-N-{[(1,1-dimethylethyl)oxy]carbonyl}glycinate
• CAS NO: 1146412-06-7
• Molecular Weight: 351.378
• Mol File: 1146412-06-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl N-{2-[(2-cyano-4-fluorophenyl)amino]ethyl}-N-{[(1,1-dimethylethyl)oxy]carbonyl}glycinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N-{2-[(2-cyano-4-fluorophenyl)amino]ethyl}-N-{[(1,1-dimethylethyl)oxy]carbonyl}glycinate(1146412-06-7)
• EPA Substance Registry System: methyl N-{2-[(2-cyano-4-fluorophenyl)amino]ethyl}-N-{[(1,1-dimethylethyl)oxy]carbonyl}glycinate(1146412-06-7)

Safety Data

• Hazardous Substances Data: 1146412-06-7(Hazardous Substances Data)

Upstream product

• 175211-73-1 methyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-N-(2-oxoethyl)glycinate 
• 61272-77-3 2-cyano-4-fluoroaniline 

Downstream Products

• 1146412-05-6 5-fluoro-2-(2-oxo-1-piperazinyl)benzonitrile hydrochloride 

Relevant articles and documents

4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: A is C1-6alkyl, C3-6cycloalkyl, -CH2-R6, -CHMe-R7, -CMe2-R7, or optionally substituted aryl; wherein, when A is optionally substituted aryl, said aryl group is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of halogen, C1-6alkyl, -CF3, C1-4alkoxy, C1fluoroalkoxy, cyano, NR8R9; and pyridyl wherein the pyridyl is optionally substituted by one methyl; R1 is chlorine, fluorine, -CF3, cyano or C1-6alkyl; R2, R3 and R5 independently are hydrogen, fluorine, chlorine, -CF3, cyano or C1-6alkyl, such that at least one of R2, R3 and R5 is other than hydrogen; R4 is hydrogen. These compounds and salts are thought to be P2X7 receptor antagonists. The invention also provides the use of the compound or salt for the manufacture of a medicament for the treatment of pain, inflammation, rheumatoid arthritis, osteoarthritis, or a neurodegenerative disease.